APOLIPOPROTEIN A1, 20 mL

PRINCIPLE

The reagent allows quantifying the level of human apolipoprotein A1 present in the sample by comparing the turbidimetric response produced with that obtained from the standard curve of known concentrations of human apolipoprotein A1. The reagent is an antiserum anti-human apolipoprotein A1 which reacts with the apolipoprotein A1 of the serum giving protein aggregates. This aggregation process produces an increase in the Abs. of the system.

DIAGNOSTIC USE

The apolipoprotein A1 (APO A1) is the most important structural protein of HDL lipoprotein, it is about 70% of total HDL lipoprotein. It is synthesized in the small intestine and in the liver. APO A1 acts as an specific activator of LCAT (lecithin cholesterol acyl transferase), the enzyme responsible for forming cholesteryl esters in plasma and to transport the cholesterol cells to the liver to be excreted. Low APO A1 concentrations can be associated with coronary heart diseases risk. Genetic disorders could also decrease APO A1 in serum or plasma, for example, Tangier disease, in which the decrease of APO A1 concentration are due to increase on cholesteryl esters in body tissues. High levels of APO A1 can be detected on patients with diet, physic exercise or ingest some drugs as oestrogens or niacin. Single test result could not be used to make a clinical diagnosis. It should integrate clinical and laboratory data.